Literature DB >> 17989337

Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Maxime J J Fleury1, Antoine Touzé, Silvia de Sanjosé, F Xavier Bosch, Joellen Klaustermeiyer, Pierre Coursaget.   

Abstract

The aim of this study was to develop a highly sensitive human papillomavirus type 31 (HPV31) neutralization assay based on the production of pseudovirions carrying luciferase. Neutralizing antibodies against HPV31 were investigated in a set of HPV31 monoclonal antibodies and in women with evidence of HPV31 infection. Neutralizing antibodies were detected in 78% of subjects with a positive enzyme-linked immunosorbent assay.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17989337      PMCID： PMC2223855          DOI： 10.1128/CVI.00292-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  24 in total

1.  Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

Authors:  A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Authors:  Raphael P Viscidi; Mark Schiffman; Allan Hildesheim; Rolando Herrero; Philip E Castle; Maria C Bratti; Ana Cecilia Rodriguez; Mark E Sherman; Sophia Wang; Barbara Clayman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-02       Impact factor: 4.254

3.  A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Authors:  Ratish Gambhira; Balasubramanyam Karanam; Subhashini Jagu; Jeffrey N Roberts; Christopher B Buck; Ioannis Bossis; Hannah Alphs; Timothy Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

5.  Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.

Authors:  R C Rose; R C Reichman; W Bonnez
Journal:  J Gen Virol       Date:  1994-08       Impact factor: 3.891

6.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Authors:  Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

7.  Natural history of human papillomavirus type 16 virus-like particle antibodies in young women.

Authors:  Gloria Y F Ho; Yevgeniy Y Studentsov; Robert Bierman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

8.  Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions.

Authors:  N D Christensen; J W Kreider; K V Shah; R F Rando
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

9.  Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

Authors:  Gloria Y F Ho; Yevgeniy Studentsov; Charles B Hall; Robert Bierman; Leah Beardsley; Michele Lempa; Robert D Burk
Journal:  J Infect Dis       Date:  2002-08-28       Impact factor: 5.226

10.  Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640
View more
  5 in total

1.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

2.  Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy.

Authors:  Maxime J J Fleury; Antoine Touzé; Pierre Coursaget
Journal:  Mol Biotechnol       Date:  2014-05       Impact factor: 2.695

3.  Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies.

Authors:  Parmjeet Randhawa; Raphael Viscidi; Joseph J Carter; Denise A Galloway; Tim D Culp; Cathy Huang; Bala Ramaswami; Neil D Christensen
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

4.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

5.  Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay.

Authors:  Jane Steele; Stuart Collins; Kaisheng Wen; Gordon Ryan; Christothea Constandinou-Williams; Ciaran B J Woodman
Journal:  Clin Vaccine Immunol       Date:  2008-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.